Description
Generic
Indications
Voriconazole is an azole antifungal pharmaceutical. It is demonstrated for utilize in patients 12 a long time of age and more seasoned within the treatment of taking after contagious infections- Invasive aspergillosis Candidemia (nonneutropenic) and spread candidiasis in skin, guts, kidney, bladder divider and wounds Esophageal candidiasis Serious contaminations caused by Scedosporium apiospermum and Fusarium Species counting Fusarium solani Patients narrow minded of, or headstrong to other treatment.
Pharmacology
Voriconazole is a triazole antifungal drug that is used to treat severe fungal infections. By inhibiting CYP450-dependent 14-alpha sterol demethylase, voriconazole binds to and inhibits ergosterol synthesis. When 14-alpha sterol demethylase is inhibited, ergosterol in the fungal cell membrane is depleted.
Administration & Dosage
Oral-
Voriconazole tablet and powder for suspension are to be taken at least one hour before or one hour following a meal
- At or over 40 kg body weight: Loading dose regimen is 400 mg or 10 ml every 12 hours (for the first 24 hours) and maintenance dose (after first 24 hours) is 200 mg or 5 ml twice daily.
- Below 40 Kg body weight: Loading dose regimen is 200 mg or 5 ml every 12 hours (for the first 24 hours) and maintenance dose (after first 24 hours) is 100 mg or 2.5 ml twice daily. Or, as directed by the registered physician.
Injection-
Invasive Aspergillosisd :
- Loading dose: 6 mg/kg 12 hourly for the first 24 hours.
- Maintenance Dose: 4 mg/kg 12 hourly.
Candidemia in nonneutropenic patients and other deep tissue Candida infections:
- Loading dose: 6 mg/kg 12 hourly for the first 24 hours.
- Maintenance Dose: 3-4 mg/kg 12 hourly.
Scedosporiosis and Fusariosis:
- Loading dose: 6 mg/kg 12 hourly for the first 24 hours.
- Maintenance Dose: 4 mg/kg 12 hourly.
Interaction
CYP3A4, CYP2C9 and CYP2C19 inhibitors and inducers: Alter Voriconazole measurement and screen for antagonistic responses or need of efficacy Voriconazole may increment the concentrations and action of drugs that are CYP3A4, CYP2C9 and CYP2C19 substrates. Decrease dosages of these other drugs and screen for antagonistic reactions Increase upkeep verbal and intravenous measurement of Voriconazole with co-administration of Phenytoin or Efavirenz
Contraindications
Co-administration of terfenadine, astemizole, cisapride, pimozide, or quinidine with Voriconazole or any other component of this drug is not recommended due to the risk of serious adverse reactions.
Due to the risk of efficacy loss, rifampin, carbamazepine, long-acting barbiturates, efavirenz, ritonavir, rifabutin, ergot alkaloids, and St. John’s Wort should not be taken together.
Side Effect
The most common side effects are abdominal pain, anemia, blurred vision, headache, chest pain, nausea and diarrhea.
Pregnancy & Lactation
Long-term exposure (treatment or prophylaxis) of more than 180 days necessitates careful consideration of the benefit-risk ratio. Long-term voriconazole treatment has been linked to squamous cell carcinoma of the skin (SCC).
Precautions & Warnings
Long-term exposure (treatment or prophylaxis) of more than 180 days necessitates careful consideration of the benefit-risk ratio. Long-term voriconazole treatment has been linked to squamous cell carcinoma of the skin (SCC).
Therapeutic Class
Antifungal preparations that aren’t antifungal
Storage Conditions
Protect from light and moisture by storing below 30°C. Keep the medicine out of children’s reach.
